Oral anticoagulation;Anticoagulación oral

Anales de Medicina Interna

Volumn 20, Issue 7, 2003, Pages 377-384

  Durán Parrondo, Carmen ^a,c   Rodriguez Moreno C ^b   Tato Herrero, F ^b   Alonso Vence, N ^b   Lado Lado, F L ^b  

^a Centro de Salud Don Benito Este   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c Serv de Atencion Primaria de Lalin   (Spain)

Author keywords

Antithrombotic therapy; Atrial fibrillation; Oral anticoagulant; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMOXICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTITHROMBOCYTIC AGENT; CEFAMANDOLE; CEFMINOX; CEFOPERAZONE; CEPHALOSPORIN DERIVATIVE; DIPYRIDAMOLE; DIPYRONE; ERYTHROMYCIN; GLIBENCLAMIDE; HEPARIN; LATAMOXEF; MACROLIDE; NATEGLINIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PENTOXIFYLLINE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TERBINAFINE; UNINDEXED DRUG; WARFARIN;

ACUTE HEART INFARCTION; ALOPECIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEMATOLOGICAL PARAMETERS; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MITRAL VALVE PROLAPSE; MULTICENTER STUDY; NAUSEA; PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; STROKE; SURGICAL PATIENT; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT INDICATION; URTICARIA;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; WARFARIN;

EID: 0042656960     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Acar J, Lung B, Boissel JP, Samama MM, Michel PL, Teppe JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in pacient with mechanical prosthetic Heart valves. Circulation 1996; 94: 2107-2112.
2. Stroke Prevention in Atrial Fibrillation Investigators (SPAF III). Adjusted dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
3. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999; 282: 2058-2067.
4. Turpie AGG, Gunstensen J, Hirsh, Nelson H, Gent M. Randomized comparison of two intensities of oral anticoagulant therapy after heart valve replacement. Lancet 1988; 1: 1242-1245.
5. a ed. Nueva Zelada 1997; 1113-1163.
6. Whitlon DS, Sadowski JA, Suttie JW. Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978; 17: 1371-1377.
7. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, and Deykin D. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. CHEST 2001; 119: 8S-21S.
8. Heras M, Fernández Ortiz A, Gómez Guindal JA, Iriarte JA, Lidón RM, Pérez gómez F, Roldán I. Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología. Revista Española de Cardiología 1999; 52: 810-820.
9. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: análisis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
10. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P., Singer DE. Antithrombotic Therapy in Atrial Fibrillation. CHEST 2001; 119: 194S-206S.
11. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-1262.
12. Petersen P, Boysen G, Godtfredsen J, Anderson ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989; 1: 175-178.
13. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527-539.
14. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl Med 1990; 323: 1505-1511.
15. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joiner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355.
16. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC y cols. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-1412.
17. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
18. Bonow RO, Carabello B, De Leon AC, Edmuns LH, Fedderly BJ, Freed MD y cols. Guidelines for the management of patients with valvular heart disease. Circulation 1998; 98: 1949-1984.
19. Stein P, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves Chest 2001; 119: 220S-227S.
20. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee Pk y cols. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective clinical trial. Circulation 1985; 72: 1059-1063.
21. Saour JN, Sieck JO, Mamo LAR y cols. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-432.
22. Altman R, Rouvier J, Gurfinkel E, Scazziota A, Turpie AGG. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-431.
23. Cairns JA, Théroux A, Lewis HD, Ezekowitz M, Meade TW. Antithrombotic Agents in Coronary Artery Disease. Chest 2001; 119: 228S-252S.
24. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfaretion after myocardial infarction. N Engl J Med 1990; 323: 147-152.
25. Salem DN, Daudelin DH, Levine HJ, Pauker SG, Eckman MH, Riff J. Antithrombotic therapy in valvular heart disease. CHEST 2001; 119: 207S-219S.
26. Geerrts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Wheeler HB. Prevention of venous thromboembolism. CHEST 2001; 119: 132S-175S.
27. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. CHEST 2001; 119: 176S-193S.
28. Bañas Llanos MH. Nuevas perspectivas en el tratamiento antitrombótico. Inf Ter Sist Nac Salud 2001; 25: 93-104.
29. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. CHEST 2001; 119: 300S-320S.
30. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-865.
31. Alonso R, Barroso C, Alvárez I, Puche N, Alcaraz. Anticoagulación oral en atención primaria. Inf Ter Sist Nac Salud 1997; 21: 89-96.
32. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. CHEST 2001; 119: 108S-121S.
33. Guerra García MM. Seguridad de medicamentos en pacientes a tratamiento con anticoagulantes orales: acenocumarol. BIM-FARMA 2001; 39: 1-4.
34. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L y cols. Managing oral anticoagulant therapy. CHEST 2001; 119: 22S-38S.
35. Brigden ML. Oral anticoagulant therapy: practical aspects of management. Postgrad Med 1996; 99: 81-102.